Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Caledonia to file preliminary economic assessment on chosen approach to develop the Bilboes sulphide gold project
-
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
-
Scatec ASA: Employee Share Purchase Programme 2024
-
Notification on the transaction concluded by manager in issuer's securities
-
Statkraft AS – Contemplating dual-currency green bond issuance
-
Pharming Group to participate in June investor conferences
-
Transaction in Own Shares
-
Voting Rights and Capital
-
Euronext completes the acquisition of Global Rate Set Systems
-
Transaction in Own Shares and Total Voting Rights
-
Total Voting Rights and Capital
-
Flash News: OKX Announces Enhancements to Portfolio Margin Mode to Optimize Trading Experience
-
BW Energy: Fixed Income Investor Meetings
-
Vallourec: Andre Lacerda Appointed Senior Vice President of South America (Tubes Activities)
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
-
Number of voting rights as of May 31, 2024
-
BW Energy: Appraisal confirms material Hibiscus field reserve increase
-
Start of Day Message
-
Market Update
-
New data with daridorexant to be presented at SLEEP 2024
-
Corbion reports the progress of its € 20 million share buyback program 27 May – 31 May 2024
-
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
-
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
-
Ontex finalizes the divestment of its business in Pakistan
-
Flash News: OKX to Support Mina Protocol's Upgrade
-
Flash News: OKX to Support Mina Protocol's Upgrade
-
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
-
NetAlly Unveils Next Generation LinkRunner® AT Network and Cable Testers
-
IXOPAY Appoints Brady Harris as CEO to Drive Global Payments Growth
-
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
-
AMD Unveils Next-Gen “Zen 5” Ryzen Processors to Power Advanced AI Experiences
-
AMD Accelerates Pace of Data Center AI Innovation and Leadership with Expanded AMD Instinct GPU Roadmap
-
AMD Extends AI and High-Performance Leadership in Data Center and PCs with New AMD Instinct, Ryzen and EPYC Processors at Computex 2024
-
Flash News: OKX Launches 100% Fee Rebate Campaign
-
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
-
Mesoblast Corporate Presentation at Investor Conference
-
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
-
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
-
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
-
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year
-
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
-
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple
